ARCHIVES

NCI advisors approve recompetition of $62 million phase II contracts program.

This article is from The Cancer Letter archive.

Vol. 30 No. 44 | November 19, 2004

Download PDF Visit The Full Archive

Related Articles

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

Study Identifies Risk Factors To Predict Contralateral Cancer

February 27, 2009

ACS Research Budget Over $82 Million

July 17, 1987

DCT Advisors OK 2 Grant Programs, Disapprove One, In NCI Effort To Improve Funding For Clinical Research

March 8, 1991

Bad News for EPO Products Brings FDA Scrutiny, Payment Curbs. FDA Issues Alert to Doctors.

February 23, 2007

In Brief: Panel Appointments On President’s Desk; Breast Cancer Treatment Workshop Planned

September 14, 1979